Migraine
Conditions
Brief summary
To develop a pragmatic migraine model the investigators will induce headache in patients with migraine without aura with a phosphodiesterase inhibitor (cilostazol). If the headache responds to sumatriptan injection, the model can be used to test new drug candidates.
Detailed description
There remains a great need for more effective anti-migraine drugs with fewer side effects. Human experimental models are valuable in early phase development of new anti-migraine drugs but useful models have not yet been developed. The investigators' group has shown that Cilostazol, a phosphodiesterase inhibitor induce headache/migraine in both healthy volunteers and in patients with migraine without aura (MO). To validate this model, the headache must respond to specific migraine treatment with sumatriptan. Hypothesis: Cilostazol induces a migraine-like headache in MO-patients and the induced headache responds to sumatriptan injection Aim: Developing a pragmatic and valid model for the testing of new anti-migraine drugs.
Interventions
DRUGCilostazol 200mg
Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
DRUGSUMAtriptan 6 MG/ML
Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
DRUGPlacebo
Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Sponsors
Danish Headache Center
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Migraine patients who meet IHS criteria for migraine with or without aura of both sexes * 18-70 years * 45-95 kg.
Exclusion criteria
* Any other type of headache then migraine without aura (except episodic tension-type headache \< 1 day per week) * Serious somatic or psychiatric disease * Pregnancy * Intake of daily medication (except oral contraceptives) * Triptan non-responders
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Difference in median headache score after sumatriptan/placebo | 2hours | The investigators will assess the outcome measures 1 year after the beginning of the study |
| difference in AUC 0-4h post treatment | 4hours | The difference in area under the curve 0-4h after treatment with sumatriptan and placebo |
Countries
Denmark
Outcome results
None listed